Chemical Compound Review:
Serotonin 5-HT2 Receptor Antagonists (2,3-dimethoxyphenyl)-[1-[2- (4...
Synonyms:
AGN-PC-00INZS, SureCN340674, CHEBI:537588, AC1Q4NRW, MDL-100,907, ...
- Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Herin, D.V., Liu, S., Ullrich, T., Rice, K.C., Cunningham, K.A. Psychopharmacology (Berl.) (2005)
- Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. Sorensen, S.M., Kehne, J.H., Fadayel, G.M., Humphreys, T.M., Ketteler, H.J., Sullivan, C.K., Taylor, V.L., Schmidt, C.J. J. Pharmacol. Exp. Ther. (1993)
- Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Taylor, J.L., Bishop, C., Ullrich, T., Rice, K.C., Walker, P.D. Neuropharmacology (2006)
- 5-HT2C receptor involvement in female rat lordosis behavior. Wolf, A., Caldarola-Pastuszka, M., DeLashaw, M., Uphouse, L. Brain Res. (1999)
- Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Winstanley, C.A., Chudasama, Y., Dalley, J.W., Theobald, D.E., Glennon, J.C., Robbins, T.W. Psychopharmacology (Berl.) (2003)
- Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Moser, P.C., Moran, P.M., Frank, R.A., Kehne, J.H. Behav. Brain Res. (1996)
- Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior. Feldman, D.J., Frank, R.A., Kehne, J.H., Flannery, R., Brown, D., Soni, S., Byrd, G., Shah, S. Pharmacol. Biochem. Behav. (1997)
- Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. Boehme, S.A., Lio, F.M., Sikora, L., Pandit, T.S., Lavrador, K., Rao, S.P., Sriramarao, P. J. Immunol. (2004)
- Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. Watabe, H., Channing, M.A., Der, M.G., Adams, H.R., Jagoda, E., Herscovitch, P., Eckelman, W.C., Carson, R.E. J. Cereb. Blood Flow Metab. (2000)
- Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907. Wadenberg, M.L., Hicks, P.B., Richter, J.T., Young, K.A. Biol. Psychiatry (1998)
- Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Carli, M., Baviera, M., Invernizzi, R.W., Balducci, C. Neuropsychopharmacology (2006)
- The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Barr, A.M., Lehmann-Masten, V., Paulus, M., Gainetdinov, R.R., Caron, M.G., Geyer, M.A. Neuropsychopharmacology (2004)
- M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Arvanov, V.L., Wang, R.Y. Neuropsychopharmacology (1998)
- M100907, a highly selective 5-HT2A receptor antagonist and a potential atypical antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice. Wang, R.Y., Arvanov, V.L. Brain Res. (1998)
- 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Millan, M.J., Peglion, J.L., Lavielle, G., Perrin-Monneyron, S. Eur. J. Pharmacol. (1997)
- 5-HT2A and 5-HT2C/5-HT1B receptors are differentially involved in alcohol preference and consummatory behavior in cAA rats. Maurel, S., De Vry, J., De Beun, R., Schreiber, R. Pharmacol. Biochem. Behav. (1999)
- Modulation of brainstem 5-HT1C receptors by serotonergic drugs in the rat. Pranzatelli, M.R., Tailor, P.T. Gen. Pharmacol. (1994)
- SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Bonaccorso, S., Meltzer, H.Y., Li, Z., Dai, J., Alboszta, A.R., Ichikawa, J. Neuropsychopharmacology (2002)
- Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. Andrée, B., Nyberg, S., Ito, H., Ginovart, N., Brunner, F., Jaquet, F., Halldin, C., Farde, L. Journal of clinical psychopharmacology. (1998)
- Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. Schmidt, C.J., Fadayel, G.M. J. Pharmacol. Exp. Ther. (1996)
- Extracellular single-unit recordings of piriform cortex neurons in rats: influence of different types of anesthesia and characterization of neurons by pharmacological manipulation of serotonin receptors. Bloms-Funke, P., Gernert, M., Ebert, U., Löscher, W. J. Neurosci. Res. (1999)
- Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Willins, D.L., Berry, S.A., Alsayegh, L., Backstrom, J.R., Sanders-Bush, E., Friedman, L., Roth, B.L. Neuroscience (1999)
- M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Wang, R.Y., Liang, X. Neuropsychopharmacology (1998)
- Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. Schmidt, C.J., Sullivan, C.K., Fadayel, G.M. J. Neurochem. (1994)
- Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. Amargós-Bosch, M., Adell, A., Bortolozzi, A., Artigas, F. J. Neurochem. (2003)
- Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Sebban, C., Tesolin-Decros, B., Ciprian-Ollivier, J., Perret, L., Spedding, M. Br. J. Pharmacol. (2002)
- M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Varty, G.B., Bakshi, V.P., Geyer, M.A. Neuropsychopharmacology (1999)
- Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Palfreyman, M.G., Schmidt, C.J., Sorensen, S.M., Dudley, M.W., Kehne, J.H., Moser, P., Gittos, M.W., Carr, A.A. Psychopharmacology (Berl.) (1993)
- Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Gründer, G., Yokoi, F., Offord, S.J., Ravert, H.T., Dannals, R.F., Salzmann, J.K., Szymanski, S., Wilson, P.D., Howard, D.R., Wong, D.F. Neuropsychopharmacology (1997)
- The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. Offord, S.J., Wong, D.F., Nyberg, S. Journal of clinical pharmacology. (1999)
- Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat. Scott, D.O., Heath, T.G. Journal of pharmaceutical and biomedical analysis. (1998)